Jennifer Trevor
Pulmonary Disease · Birmingham, ALNPI 1417112871
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,456 of the $19,027 with a category attached, or 70.7%. 5 manufacturers reported payments, led by GSK at 58.0% of the total. Reporting peaked in 2024 at $12,007 and has fallen 52.9% since, to $5,656 in 2025. Among pulmonary disease clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $311.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- Sanofi$7K
- AstraZeneca$970
- Regeneron Healthcare Solutions, Inc.$109
- Genentech, Inc.$79
Across 12 payments — averaging $6806.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$77K
- Novartis$4K
- Acerta Pharma LLC$258
What the payments were for
- Consulting fees$13,45671%
- Travel & lodging$2,52013%
- Food & beverage$3,05116%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $11,026 |
| Sanofi | 15 | $6,842 |
| AstraZeneca | 8 | $970 |
| Regeneron Healthcare Solutions, Inc. | 3 | $109 |
| Genentech, Inc. | 2 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,027 in reported general payments places this provider in the 90th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 62 | $221,209 |
| Dupixent SyringeDupilumab | 45 | $160,939 |
| TezspireTezepelumab-Ekko | 26 | $109,110 |
| NucalaMepolizumab | 24 | $85,094 |
| XolairOmalizumab | 14 | $72,904 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $35,357 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $9,923 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $6,723 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,655 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,950 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,852 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,987 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $1,177 |
| Azithromycin | 17 | $330 |
| Montelukast Sodium | 33 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $11,026 | $130,37588 claims |
| AstraZenecaTezspire, Symbicort | $970 | $112,05937 claims |
| Genentech, Inc.Xolair | $79 | $72,90414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$134K
- Amanda DenhamBirmingham$45K
- Bryan GarciaBirmingham$29K
- Steven RoweBirmingham$27K
- Peter MorrisBirmingham$25K
- Russell BeatyBirmingham$24K
- Jay HeideckerBirmingham$21K
- Jason FainBirmingham$18K
- Jeffrey GarnerBirmingham$14K
- Brian FlanaganBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.